Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-19
2011-07-19
Dahle, Chun (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388220, C530S388700, C530S391100, C530S391300, C424S130100, C424S133100, C424S134100, C424S138100, C424S141100, C424S143100, C424S152100, C424S153100, C424S156100, C424S178100, C424S001210, C424S001210, C424S001210, C424S001210, C424S001210
Reexamination Certificate
active
07982011
ABSTRACT:
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers. Additionally, the invention provides a method of increasing the cytotoxicity of forms ofPseudomonasexotoxin A (“PE”) with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.
REFERENCES:
patent: 4892827 (1990-01-01), Pastan et al.
patent: 5602095 (1997-02-01), Pastan et al.
patent: 5608039 (1997-03-01), Pastan et al.
patent: WO 00/73346 (2000-12-01), None
patent: WO 03/027135 (2003-04-01), None
Mansfield et al. Blood. (1997) 90:2020-2026).
Pai et al. PNAS (1991) 88:3358-3362.
Kondo et al. JBC (1988) 263:9470-9475.
Debinski et al. Bioconj. Chem. (1994) 5:40-46.
Exhibit A. PubMed Search PE40. Aug. 26, 2010. pp. 1-20.
Exhibit B. PubMed Search PE38. Aug. 26, 2010. pp. 1-21.
Exhibit C. PubMed Search PE38QQR. Aug. 26, 2010. pp. 1-7.
Exhibit D. PubMed Search PE38KDEL. Aug. 26, 2010. pp. 1-10.
Exhibit E. PubMed Search PE4E. Aug. 26, 2010. pp. 1-3.
Exhibit F. PubMed Search PE35. Aug. 26, 2010. pp. 1-20.
Exhibit G. Aug. 26, 2010. pp. 1-39.
Bang, Sookhee et al.; “HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity and therapeutic index”; 2004,Proceedings of the American Association for Cancer Research Annual Meeting, vol. 45, p. 144.
Bang, Sookhee et al.; “HA22 (R490A) is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity”; 2005,Clinical Cancer Researchvol. 2, pp. 1545-1550.
Beers, Richard et al.; “Immunotoxins with Increased Activity against Epidermal Growth Factor Receptor vIII-expressing Cells Produced by Antibody Phage display”; 2000,Clinical Cancer Researchvol. 6 pp. 2835-2843.
Brinkmann, Ulrich et al.; “Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice”; 1992Proceedings of the National Academy of Science, vol. 89, pp. 3065-3069.
Chowdhury, Partha S. et al.; “Improving antibody affinity by mimicking somatic hypermutation in vitro”; 1999,Nature Biotechnology, vol. 17, pp. 568-572.
Decker, Thomas et al.; “Induction of Caspase-Dependent Programmed Cell Death in B-CLL Cells by Recombinant Anti-CD22 Immunotoxins”; 2003,Blood, vol. 102, No. 11, p. 439a.
Ho, Mitchell et al.; “In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin”; 2005,The Journal of Biological Chemistry, vol. 280, No. 1, pp. 607-617.
Kreitman, Robert J.; “Chimeric fusion proteins—Pseudomonasexotoxin-based”; 2001,Current Opinion in Investigational Drugs, vol. 2, No. 9, pp. 1282-1293.
Salvatore, Giuliana et al.; “Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display”; 2002,Clinical Cancer Research, vol. 8, pp. 995-1002.
Tsutsumi, Yasuo et al.; “Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity”; 2000,Proceedings of the National Academy of Science, vol. 97, No. 15, pp. 8548-8553.
Yates, Susan P. et al.; “A Catalytic Loop within Pseudomonas aeruginosa Exotoxin A Modulates Its Transferase Activity”; 2001,The Journal of Biological Chemistry, vol. 276, No. 37, pp. 35029-35036.
Bang Sookhee
Ho Mitchell
Pastan Ira H.
Dahle Chun
Kilpatrick Townsend & Stockton LLP
The United States of America as represented by the Secretary of
LandOfFree
Mutated anti-cd22 antibodies and immunoconjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutated anti-cd22 antibodies and immunoconjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutated anti-cd22 antibodies and immunoconjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741177